Access Consortium Strategic Plan 2021-2024

On 22 June 2021 the Access consortium (comprising the national regulatory authorities of Australia, Canada, Singapore, Switzerland, and the UK) published its Strategic Plan 2021-2024.

The Consortium is committed to maximizing collaboration by aligning regulatory and policy approaches, reducing duplication, and facilitating our populations’ access to high quality, safe and effective health products. This group originally consisted of the regulatory authorities in Australia, Canada, Singapore and Switzerland (previously referred to as ACSS). With the addition of the United Kingdom’s Medicines and Healthcare products Regulatory Agency, a leading international medicines regulator, in October 2020, the Consortium changed its name to Access, reflecting the principal goal of increasing our populations’ access to health products through international collaboration and work-sharing. The Access Consortium now represents a collective population base of 150M.

This plan will be a guide toward enhanced efficiency of our national regulatory systems, while optimizing synergies and alignment between regulatory authorities and reducing duplication for industry.

Read the pdf 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /